Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

详细信息    查看全文

• 作者：Alain Hendlisz (1)
  Vassilis Golfinopoulos (1)
  Amelie Deleporte (1)
  Marianne Paesmans (2)
  Hazem El Mansy (1)
  Camilo Garcia (3)
  Marc Peeters (4)
  Lieven Annemans (5)
  Caroline Vandeputte (1)
  Marion Maetens (1)
  Ivan Borbath (6)
  Damien Dresse (7)
  Ghislain Houbiers (8)
  Michael Fried (9)
  Ahmad Awada (1)
  Martine Piccart (1)
  Jean-Luc Van Laethem (10)
  Patrick Flamen (3)
  
• 关键词：Colon cancer ; Adjuvant ; Early assessment ; Chemosensitivity ; FDG ; PET ; PET/CT
• 刊名：BMC Cancer
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：13
• 期：1
• 全文大小：401KB
• 参考文献：1. Parkin DM, Bray F, Ferlay , Pisani P: Global cancer statistics. / CA Cancer J Clin 2005, 55:74-08. CrossRef
  2. American Joint Committee on Cancer (AJCC): / AJCC Cancer Staging Manual. 7th edition. Edited by: Edge SB, Byrd DR, Carducci MA. New York: Springer; 2009.
  3. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. / J Natl Cancer Inst 1988, 80:30-6. CrossRef
  4. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. / N Engl J Med 2004, 350:2343-351. CrossRef
  5. Chau I, Cunningham D: Adjuvant therapy in colon cancer—what, when and how? / Annals of Oncol 2006, 17:1347-359. CrossRef
  6. Lenihan DJ, Cardinale DM: Late Cardiac Effects of Cancer Treatment. / J Clin Oncol 2012. Sep 24. [Epub ahead of print]
  7. Ahles TA, Root JC, Ryan EL: Cancer- and Cancer Treatment-Associated Cognitive Change: An Update on the State of the Science. / J Clin Oncol 2012. Sep 24. [Epub ahead of print]
  8. Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. / J Clin Oncol 2012,30(29):3578-587. CrossRef
  9. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB: Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. / J Clin Oncol 2012. [Epub ahead of print]
  10. Miller AB, Hogestraeten B, Staquet M, Winkler A: Reporting results of cancer treatment. / Cancer 1981, 47:207-14. CrossRef
  11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. / J Natl Cancer Inst 2000, 92:205-16. CrossRef
  12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). / Eur J Cancer 2009, 45:228-47. CrossRef
  13. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M: Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18?F] fluorodeoxyglucose positron emission tomography. / J Clin Oncol 2006, 24:5366-372. CrossRef
  14. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M: FDG-PET after 1?cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. / Cancer 2006, 107:2678-687. CrossRef
  15. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M: Impact of [18?F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. / J Clin Oncol 2012. Oct 29. [Epub ahead of print]
  16. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW: Time course of early response to chemotherapy in non-small cell lung cancer patients with 18?F-FDG PET/CT. / J Nucl Med 2007, 48:744-51. CrossRef
  17. Schaake EE, Kappers I, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren H, Klomp HM: Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. / J Clin Oncol 2012, 30:2731-738. CrossRef
  18. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. / J Clin Oncol 2006, 24:4692-698. CrossRef
  19. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, H?fler H, Fink U, Peschel C, Schwaiger M, Siewert JR: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. / Lancet Oncol 2007, 8:797-05. CrossRef
  20. Zum Büschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ: 18?F-FDG PET–Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial. / J Nucl Med 2011, 52:1189-196. CrossRef
  21. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ: Chemotherapy response evaluation with FDG–PET in patients with colorectal cancer. / Ann Oncol 2008, 19:348-52. CrossRef
  22. Bystr?m P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren P, Fr?din JE, Glimelius B: Early prediction of response to first-line chemotherapy by sequential [18?F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. / Ann Oncol 2009, 20:1057-061. CrossRef
  23. Kim J, Choi S, Yi H, Lim J, Lee M, Hyun I, Kim C: Prediction of response to chemotherapy using sequential F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with metastatic colorectal cancer. / J Clin Oncol 2007,25(18S):2536. Annual Meeting Proceedings Part I
  24. Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P: Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. / Ann Oncol 2012 Jul,23(7):1687-3. CrossRef
  25. Calvo FA, Domper M, Matute R, Martínez-Lázaro R, Arranz JA, Desco M, Alvarez E, Carreras JL: 18?F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. / Int J Radiat Oncol Biol Phys 2004, 58:528-35. CrossRef
  26. Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, Gava M, Fanti S, Mariani G, Muzzio PC, Rubello D: Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. / Eur J Nucl Med Mol Imaging 2007, 34:1583-593. CrossRef
  27. Romas N, Kilpatrick NW, Ntouroupi TG: Analysis of circulating tumour cells in prostate, colorectal and ovarian cancer using robotic microscopy [abstract]. / J Clin Oncol 2008., 26: May 20 suppl; abstr 11084
  28. Meropol NJ, Cohen SJ, Iannotti N, Saidman BH, Sabbath KD, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Punt CJA: Circulating tumour cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. / J Clin Oncol 2007,25(18S):4010. / ASCO Annual Meeting Proceedings Part I. 2007
  29. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: / J Clin Oncol. 2008,26(19):3213-221. Circulating tumor cells, progression-free survival, and overall survival in metastatic colorectal cancer: A subgroup analysis of a large multicenter study CrossRef
  30. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: Relationship of circulating tumour cells to tumour response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. / J Clin Oncol 2008, 26:3213-221. CrossRef
  31. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumour cells, disease progression, and survival in metastatic breast cancer. / N Engl J Med 2004, 351:781-1. CrossRef
  32. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW: Circulating tumour cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. / Clin Cancer Res 2006, 12:4218-224. CrossRef
  33. Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT: Variation of circulating tumour cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. / Ann Oncol 2008, 19:891-97. CrossRef
  34. Uen YH, Lu CY, Tsai HL, Yu FJ, Huang MY, Cheng TL, Lin SR, Wang JY: Persistent presence of postoperative circulating tumour cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. / Ann Surg Oncol 2008, 15:2120-128. CrossRef
  35. Stratton MR, Campbell PJ, Futreal PA: The cancer genome. / Nature 2009, 458:719-24. CrossRef
  36. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B: Detection and quantification of mutations in the plasma of patients with colorectal tumors. / Proc Natl Acad Sci USA 2005,102(45):16368-6373. CrossRef
  37. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G: Immunogenic cancer cell death: a key-lock paradigm. / Curr Opin Immunol 2008, 20:504-11. CrossRef
  38. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4-?CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. / Cancer Immunol Immunother 2007, 56:641-48. CrossRef
  39. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G: Immunogenic death of colon cancer cells treated with oxaliplatin. / Oncogene 2010, 29:482-91. CrossRef
  40. Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Martinez F, Moreno J, Hernandez R, Navarro-Vigo M: Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first line oxaliplatin/fluoropyrimidine. / Oncology 2007, 72:364-70. CrossRef
  41. Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-Fluorouracyl-based chemotherapy. / Clin Cancer Res 2004, 10:5880-888. CrossRef
  42. Bosch TM, Meijerman I, Beijnene JH, Schellens JHM: Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. / Clin Pharmacokinet 2006, 45:253-85. CrossRef
  43. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ: Association between glutathione S-transferase P1, T1 and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. / J Natl Cancer Inst 2002, 94:936-42. CrossRef
  44. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. / Science 2006,313(5795):1960-964. CrossRef
  45. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. / J Clin Oncol 2011, 29:610-18. CrossRef
  46. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. / N Engl J Med 2005, 353:2654-666. CrossRef
  47. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. / J Clin Oncol 2009, 27:5944-951. CrossRef
  48. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS: Controlled Trial of Fluorouracil and Low-dose Leucovorin Given for 6?months as postoperative Adjuvant Therapy for Colon Cancer. / J Clin Oncol 1997, 15:246-50.
  49. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito D, Morton RF, Tschetter LK, Barlow JF: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. / J Clin Oncol 1989, 7:1447-456.
  50. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/190/prepub
  
• 作者单位：Alain Hendlisz (1)
  Vassilis Golfinopoulos (1)
  Amelie Deleporte (1)
  Marianne Paesmans (2)
  Hazem El Mansy (1)
  Camilo Garcia (3)
  Marc Peeters (4)
  Lieven Annemans (5)
  Caroline Vandeputte (1)
  Marion Maetens (1)
  Ivan Borbath (6)
  Damien Dresse (7)
  Ghislain Houbiers (8)
  Michael Fried (9)
  Ahmad Awada (1)
  Martine Piccart (1)
  Jean-Luc Van Laethem (10)
  Patrick Flamen (3)
  
  1. Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  2. Data Center, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  3. Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  4. Department of Oncology, Antwerp University Hospital, Antwerp, Belgium
  5. Health Economics, Department of Public Health, Ghent University, Ghent, Belgium
  6. Gastroenterology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
  7. Service de Chirurgie Abdominale et Générale, Centre Hospitalier Régional La Citadelle, Liège, Belgium
  8. Service d’Oncologie et d’Hématologie, CH Saint Joseph, Liège, Belgium
  9. Oncology department, Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium
  10. Gastroenterology Department, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
  
• ISSN：1471-2407

文摘

Background Surgery is a curative treatment for patients with locally advanced colon cancer, but recurrences are frequent for those with stage III disease. FOLFOX adjuvant chemotherapy has been shown to improve recurrence-free survival and overall survival by more than 20% and is nowadays considered a standard of care. However, the vast majority of patients will not benefit from receiving cytotoxic drugs because they have either already been cured by surgery or because their tumor cells are resistant to the chemotherapy, for which predictive factors are still not available. Identifying which patients are unlikely to respond to adjuvant chemotherapy from among those who are eligible for such treatment would be a major step towards treatment personalization. It would spare such patients from unnecessary toxicities and would improve the allocation of societal healthcare resources. Methods/design PePiTA is a prospective, multicenter, non-randomised trial built on the hypothesis that preoperative chemosensitivity testing using FDG-PET/CT before and after one course of FOLFOX can identify the patients who are unlikely to benefit from 6?months of adjuvant FOLFOX treatment for stage III colon cancer. The study’s primary objective is to examine the ability of PET/CT-assessed tumor FDG uptake after one course of preoperative chemotherapy to predict the outcome of adjuvant therapy, as measured by 3-year disease-free survival. Secondary objectives are to examine the predictive value of changes in PET/CT-assessed tumor FDG uptake on overall survival, to define the best cut-off value of FDG uptake for predicting treatment outcome, and to analyse the cost-effectiveness of such preoperative chemo-sensitivity testing. At study planning, exploratory translational research objectives were 1) to assess the predictive value of circulating tumor cells for disease-free survival, 2) to examine the predictive value of single nucleotide polymorphisms for disease-free survival with respect to genes related either to toxicity or to drug targets, 3) to assess genomic rearrangements associated with response or resistance to FOLFOX treatment, 4) to identify an immunologic signature associated with metabolic tumor response to FOLFOX therapy and, finally, 5) to create a bank of frozen tumor samples for future studies. Discussion PePiTA is the first study to use the primitive tumor chemosensitivity assessed by metabolic imaging as a guidance for adjuvant therapy in colon cancer. It could pave the way for tailoring the treatment and avoiding useless toxicities for the patients and inadequate expenses for the society. It could also give an interesting insight into tumoral heterogeneity, resistance to chemotherapy, genetic predisposants to oxaliplatin toxicity and immune response to cancer. EudraCT number 2009-011445-13 Trial registration ClinicalTrials.gov number, NCT00994864